Biotech Gainers: XOMA Corp (NASDAQ:XOMA), Vanda Pharmaceuticals (NASDAQ:VNDA), 22nd Century Group (NYSEMKT:XXII), Repligen Corporation (NASDAQ:RGEN)

Canaccord raised its price target for XOMA Corp (NASDAQ:XOMA) shares to $10 from $8 despite the erosive osteoarthritis of the hand trial failure. The firm said the setting was never part of its model and that its raised target reflects the pyoderma gangrenosum data. Canaccord reiterates a Buy rating on XOMA. XOMA Corp (NASDAQ:XOMA) shares after opening at $3.99 moved to $4.22 on last trade day and at the end of the day closed at $4.20. Company price to sales ratio in past twelve months was calculated as 12.61 and price to cash ratio as 3.68. XOMA Corp (NASDAQ:XOMA) showed a negative weekly performance of -10.06%.

On April 9, 2014, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued a press release announcing, among other things, that HETLIOZ has become available for shipment to pharmacies in the United States. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares advanced 5.05% in last trading session and ended the day on $13.31. VNDA return on equity ratio is recorded as -76.90% and its return on assets is -15.00%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) yearly performance is 193.82%.

22nd Century Group (NASDAQ:XXII)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a research note issued to investors on Monday, American Banking News reports. They currently have a $8.00 target price on the stock. Chardan Capital’s price target points to a potential upside of 73.91% from the company’s current price. 22nd Century Group Inc. (NYSEMKT:XXII) shares moved up 26.36% in last trading session and was closed at $2.78, while trading in range of $2.15 – $3.20. 22nd Century Group Inc. (NYSEMKT:XXII) year to date (YTD) performance is 29.91%.

Repligen Corporation (NASDAQ:RGEN) will replace Hi-Tech Pharmacal Co., Inc. in the S&P SmallCap 600 after the close of trading on Thursday, April 17. Repligen Corporation (NASDAQ:RGEN) weekly performance is 6.05%. On last trading day company shares ended up $14.37. Repligen Corporation (NASDAQ:RGEN) distance from 50-day simple moving average (SMA50) is -1.59%. Analysts mean target price for the company is $16.00.